CYP3A5 genotyping-guided dosing versus weight-based dosing in a multi-ethnic population of kidney transplant recipients

View Full Paper

Ask AI

Bookmark

Authors

Discussion

Pilot study shows CYP3A5-guided dosing improves target levels in multiethnic kidney transplant recipients, suggesting dosing strategy impact.

CYP3A5-guided dosing may achieve target levels faster after kidney transplantation, resulting in shorter times to trough levels by about 2 days.
Initial tacrolimus dosing was higher in the CYP3A5-guided group at 0.16 mg/kg/day, compared to 0.12 mg/kg/day in the weight-based group, with significant p values.
The study found higher rates of hyperkalemia in the CYP3A5-guided group, with 53.8% affected compared to 21.1% in the weight-based cohort.
Ethnic differences in CYP3A5 expression were noted, with variations between Chinese and non-Chinese participants being statistically significant at p = .02.

Lim et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

View Full Paper

Ask AI

Bookmark

Authors

Pilot study shows CYP3A5-guided dosing improves target levels in multiethnic kidney transplant recipients, suggesting dosing strategy impact.

CYP3A5-guided dosing may achieve target levels faster after kidney transplantation, resulting in shorter times to trough levels by about 2 days.
Initial tacrolimus dosing was higher in the CYP3A5-guided group at 0.16 mg/kg/day, compared to 0.12 mg/kg/day in the weight-based group, with significant p values.
The study found higher rates of hyperkalemia in the CYP3A5-guided group, with 53.8% affected compared to 21.1% in the weight-based cohort.
Ethnic differences in CYP3A5 expression were noted, with variations between Chinese and non-Chinese participants being statistically significant at p = .02.

Lim et al. (2025) studied this question.

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark